This is a modest pipeline-expansion event for a clinical-stage biotech with no revenue. The collaboration validates OP-3136's combinability but carries no near-term financial catalyst. Watch for ASCO data on May 30, 2026, which could provide the first clinical proof-of-concept for OP-3136. Historical pattern of negative drift on OLMA neutral news suggests caution.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $13.55entry
- T+1 · 6mo ago −4.72%α −4.74% · $12.91
- T+5 · 6mo ago −21.11%α −22.32% · $10.69
- T+20 · 5mo ago −15.42%α −13.48% · $11.46
- T+60 · 3mo ago −16.53%α −19.26% · $11.31
Price Chart
How similar events traded
Executive Summary
Olema Oncology announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will enroll approximately 36 patients and is expected to start in H2 2026.
Key Facts
- Olema and Bayer entered a clinical trial collaboration for OP-3136 (KAT6 inhibitor) + darolutamide in mCRPC.
- Phase 1b/2 study will enroll ~36 patients; initiation expected in H2 2026.
- Bayer supplies darolutamide; Olema leads the study and retains full global commercial rights to OP-3136.
- Initial Phase 1 monotherapy data for OP-3136 to be presented at ASCO on May 30, 2026.
- No upfront or milestone payments disclosed; deal is a drug-supply collaboration only.
Financial Impact
No financial terms disclosed; Bayer provides darolutamide at no cost; Olema bears study costs.
Risk Factors
- Phase 1b/2 study may fail to show efficacy or safety in mCRPC.
- No financial terms disclosed, deal provides no capital infusion.
- OP-3136 is early-stage (Phase 1); clinical and regulatory risks are high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300930 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers